Salud financiera de hoja de balance de Sino Biopharmaceutical
Salud financiera controles de criterios 5/6
Sino Biopharmaceutical tiene un patrimonio de accionistas total de CN¥38.2B y una deuda total de CN¥12.2B, lo que sitúa su ratio deuda-patrimonio en 32%. Sus activos y pasivos totales son CN¥63.6B y CN¥25.4B respectivamente. El BAIT de Sino Biopharmaceutical es de CN¥5.4B, por lo que su ratio de cobertura de intereses es de -46.8. Tiene efectivo e inversiones a corto plazo que ascienden a CN¥12.6B.
Información clave
32.3%
Ratio deuda-patrimonio
CN¥12.35b
Deuda
Ratio de cobertura de intereses | -46.8x |
Efectivo | CN¥14.12b |
Patrimonio | CN¥38.17b |
Total pasivo | CN¥25.43b |
Activos totales | CN¥63.60b |
Actualizaciones recientes sobre salud financiera
Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet
Dec 03Recent updates
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings
Apr 21What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates
Apr 03Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 20Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon
Dec 18Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate
Nov 17We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?
May 26Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?
Feb 09Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Nov 11Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?
Jul 08Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued
Jan 22Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet
Dec 03Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Oct 19Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02
Sep 03These 4 Measures Indicate That Sino Biopharmaceutical (HKG:1177) Is Using Debt Reasonably Well
Aug 27Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 38% Undervaluation?
Jul 14Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (CN¥23.8B) de 1177 superan a sus pasivos a corto plazo (CN¥22.6B).
Pasivo a largo plazo: Los activos a corto plazo de 1177 (CN¥23.8B) superan a sus pasivos a largo plazo (CN¥2.8B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: 1177 tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de 1177 ha crecido de 9.1% a 32% en los últimos 5 años.
Cobertura de la deuda: La deuda de 1177 está bien cubierta por el flujo de caja operativo (40.8%).
Cobertura de intereses: 1177 gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.